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is unclear but inﬂammation, and speciﬁcally macrophage activation, likely plays a key role.
Macrophages have the ability to promote the repair of injured tissue by regulating
transitions through different phase of the healing response. In the current review we
compare and contrast the healing and inﬂammatory responses between spinal cord
injuries and tissues that undergo complete wound resolution. Through this comparison,
we identify key macrophage phenotypes that are inaptly triggered or absent after spinal
cord injury and discuss spinal cord stimuli that contribute to this maladaptive response.
Sequential activation of classic, pro-inﬂammatory, M1 macrophages and alternatively
activated, M2a, M2b, and M2c macrophages occurs during normal healing and facilitates
transitions through the inﬂammatory, proliferative, and remodeling phases of repair. In
contrast, in the injured spinal cord, pro-inﬂammatory macrophages potentiate a prolonged
inﬂammatory phase and remodeling is not properly initiated. The desynchronized
macrophage activation after spinal cord injury is reminiscent of the inﬂammation present
in chronic, non-healing wounds. By reﬁning the role macrophages play in spinal cord
injury repair we bring to light important areas for future neuroinﬂammation and
neurotrauma research.
This article is part of a Special Issue entitled SI: Spinal cord injury.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC
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The injured spinal cord does not regenerate. Instead spinal
cord injury (SCI) induces a chronic wound state that undergoes
expansion and maintained demyelination resulting in imp-
aired recovery and progressive tissue degeneration. Maladap-
tive inﬂammation, speciﬁcally macrophage activation, is likely
a contributor. In mammals, macrophages, derived from blood
monocytes and activated microglia, indeﬁnitely persist at the
site of SCI (Donnelly and Popovich, 2008). Macrophage deple-
tion improves recovery (Popovich et al., 1999) and augmenting
reparative macrophage phenotypes increases axon growth
and motor function (Schwartz and Yoles, 2006). Collectively,
these ﬁndings provide evidence that the natural macrophage
response to SCI does not promote complete wound resolution.
In contrast, tissue repair and functional recovery occur after
skin or muscle injuries through three sequential and over-
lapping wound healing phases. These include an inﬂammatory
phase with phagocytic removal of cellular debris; a pro-
liferative phase involving revascularization, angiogenesis and
extracellular matrix deposition (ECM); and a remodeling phase
involving wound retraction, inﬂammatory resolution, replace-
ment of lost tissue and ultimately tissue homeostasis (Gurtner
et al., 2008). Interruption of this delicate process leads to tissue
destruction and a non-healing chronic wound state. Tissue
repair has emerged as an active process in which macrophages
play essential roles and orchestrate transitions within and
among all three phases (Novak and Koh, 2013a).
Macrophages assume a wide spectrum of different functional
states that can inﬂuence repair. Macrophage phenotypes are
determined by the microenvironment and can change in
response to new stimuli (Stout and Suttles, 2004). This “func-
tional adaptivity” enables macrophage to contribute to all phases
of repair by promoting inﬂammation, removing injurious trig-
gers, depositing ECM, stimulating cell proliferation, and releasing
anti-inﬂammatory cues. When activated out of sequence,however, macrophages have the potential to interrupt different
phases of repair and persistent macrophage activation can lead
to maladaptive, chronic inﬂammation and dysfunctional wound
healing (Werdin et al., 2009; Nathan and Ding, 2010).
We now understand that SCI activates macrophages with
different functional phenotypes (Kigerl et al., 2009; David and
Kroner, 2011; Shechter and Schwartz, 2012; Ren and Young, 2013;
Shin et al., 2013; Thawer et al., 2013). There are similarities
between the types of macrophages activated during various
phases of normal tissue repair (i.e. muscle and skin healing)
and after SCI, however these similarities have not been examined
in detail. Recent reviews have compared the overall wound
healing responses between spinal cord and skin/muscle injuries
and have examined the glial response to CNS injuries and disease
(Shechter and Schwartz, 2013; Burda and Sofroniew, 2014). The
role of resident vs. recruitedmacrophages (derived frommicroglia
and monocytes respectively) is also a current focus and will not
be discussed in detail (David and Kroner, 2011; Hawthorne and
Popovich, 2011; London et al., 2013; Ren and Young, 2013). In this
review we will compare and contrast the functions and pheno-
types of macrophages needed during the progression of normal
tissue repair with the macrophage response to SCI. Further, we
will discuss factors that may contribute to different modes of
macrophage activation after SCI. Throughout this review we will
highlight areas that need to be explored in order to increase our
understanding of inﬂammatory-mediated healing after SCI.2. Overview of the macrophage response to
spinal cord injury
A stereotypical, sequential inﬂammatory cascade is initiated
after spinal cord trauma. Neutrophils are recruited from the
circulation and CNS glia (astrocytes and microglia) are activated
within the ﬁrst 24 h after SCI. Shortly thereafter (2–3 days post-
injury; dpi), blood monocytes migrate to the injury site where
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and morphologically indistinguishable from activated microglia.
Subtle differences in the kinetics and magnitude of the macro-
phage response have been observed between different strains
and species of animals (and humans); however, these cellular
reactions are widely recognized as being pivotal in the patholo-
gical sequelae of all forms of mammalian SCI (Donnelly and
Popovich, 2008). Regardless of the cause of SCI, in both basic
science and clinical observations, macrophages persist at the
injury site indeﬁnitely (Donnelly and Popovich, 2008). The timing
and distribution of monocyte- and microglia-derived macro-
phage activation after SCI has been reviewed previously and
for more information readers are referred to Donnelly and
Popovich (2008), David and Kroner (2011), Gensel et al. (2011)
and Ren and Young (2013).3. Macrophage activation and wound repair
The speciﬁc kinetics of the different healing phases depend
upon the injury severity but are also affected by age of theNORMAL
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In the cases of normal tissue repair, after skin or muscle
injury, the inﬂammatory phase lasts 1–2 days, the proliferation
phase peaks 1 week post-injury, and the remodeling is
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(Gurtner et al., 2008). Macrophages with speciﬁc phenotypes
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repair program (see Fig. 1) (Novak and Koh, 2013a).
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pro-reparative, later stage, M2 macrophages (Fig. 1 and Table 1).
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Table 1 – Properties of wound healing macrophages. References and abbreviations can be found in the manuscript.
M1 (classical) M2 (alternatively-activated)
Subtype M1 M2a M2b M2c
Stimuli INFyþLPS/TNF-a IL-4 or IL-13 TLRsþimmune
complexes
IL-10
Common
features/
deﬁning
markers
↑ROS, ↑IL-12, ↓IL10 ↓ROS ↓ROS, ↑IL-10, ↓IL-12 ↓ROS
IL-1B, TNF-α, IL-6, CD16,
CD32, CCL2, CD86, MARCO,
iNOS
Arg-1, Ym1, CD206, Fizz-1, TREM2,
IGF-1, IL1RN
IL-6, VEGF, IGF-1,
CD86, TNF-α, CD64
TGF-B, CD206, CD163,
SLAM, Sphk-1, THBS1,
HMOX-1
Signaling
factors
NFκ-B, STAT1, IRF5, AP-1 STAT6 STAT3
KFL2, IRF4, PPARs
Functions
in normal
healing
Pro-inﬂammatory Wound healing Immunoregulatory Immunosuppressive
Boost inﬂammation, debris
removal, sterilization,
apoptotic cell removal
Anti-inﬂammatory, cell
proliferation, cell migration,
growth factors, apoptotic cell
removal
Cell maturation, tissue
stabilization,
angiogenesis, ECM
synthesis
inﬂammatory
resolution, tissue repair,
ECM synthesis, growth
factors
Additional
functions in
CNS injury
Causes axon dieback Remyelination, axon
regeneration/reduces dieback
Axon regeneration/
reduces dieback???
Remyelination???
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chemokines (e.g. chemokine (C–C motif) ligand17 (CCL17),
CCL18 and CCL22) to attract anti-inﬂammatory leukocytes, inc-
rease phagocytic receptors, and upregulate ECM components
and growth factors (Mosser and Edwards, 2008; Van Assche,
2011; Galli etal., 2011). These mediators allow M2-type macro-
phages to tune inﬂammatory responses, scavenge debris, and
promote tissue remodeling and repair. Collectively, this
sequential M1–M2 macrophage response results in successful
wound healing in the cases of skin and muscle injuries (Fig. 1).
Deﬁning speciﬁc phenotypes in vivo is challenging due to
various environmental and tissue speciﬁc stimuli that con-
tribute to macrophage activation (Novak and Koh, 2013b;
Martinez and Gordon, 2014). In addition, macrophages exhibit
functional adaptivity and can change phenotypes in response
to new stimuli (Stout and Suttles, 2004). Therefore, in vitro-
deﬁned phenotypes oversimplify the macrophage activation
continuum but provide a useful platform of comparison
among different wound repair systems. Using this classiﬁca-
tion system we can model macrophage-mediated wound rep-
air as a progression through M1–M2c macrophage activation
(see Fig. 1 and Table 1).
The inﬂammatory phase consists of macrophages with both
M1 and M2a phenotypes (Fig. 1) (Lech and Anders, 2013).
Evidence of M1 macrophages comes from the secretion of
the pro-inﬂammatory cytokines IL-1, tumor necrosis factor α
(TNF-α), and IL-6 (Novak and Koh, 2013a). M2a macrophages
express high levels of arginase-1 and Ym1 during this early
stage. Macrophages in the early proliferative phase continue to
secrete pro-inﬂammatory cytokines but transition toward the
release of IL-10 and some anti-inﬂammatory markers (Novak
and Koh, 2013a). Interestingly, macrophages in this phase do
not signal through signal transducers and activators of tran-
scription 6 (STAT6), a traditional M2a activation pathway and
instead adopt a different M2 phenotype (Daley et al., 2010).
Given the mixed pro- and anti-inﬂammatory cytokines
released and the increase in IL-10 expression, macrophages
in the proliferative phase most easily map onto the M2b
phenotype (Table 1 and Fig. 1) (Mantovani et al., 2004;Martinez et al., 2008; Lech and Anders, 2013). During later
proliferative stages the M2b-mediated IL-10 release likely
stimulates activation of M2c macrophages as evidenced by
increased expression of prototypical M2c marker, transforming
growth factor-β (TGF-β; Table 1) (Mantovani et al., 2004; Novak
and Koh, 2013a). The remodeling phase is dominated primarily
by M2c macrophages as indicated by high TGF-β and CD206 (i.e.
mannose receptor) expression with concurrent decreases in
arginase-1 (Lech and Anders, 2013; Novak and Koh, 2013a)
(Fig. 1). Eventually, as remodeling is complete macrophages
adopt a deactivated phenotype and inﬂammation resolves.
In successful wound repair macrophage numbers return to
normal levels within weeks of injury in parallel with the timing of
wound closure and healing (Sindrilaru et al., 2011). In contrast,
wounds that do not heal within 3 months are considered chronic
(Werdin et al., 2009) and persistent macrophage activation is a
hallmark of this chronic condition (Sindrilaru et al., 2011).
Sustained, improper macrophage activation disrupts transitions
among different phases of repair. For example, chronic venous
ulcers (CVU) are the most common type of chronic wound and in
CVUsmacrophages fail to switch from anM1 to anM2 phenotype
(Werdin et al., 2009; Sindrilaru et al., 2011). The resolution interval,
the point at which cells are reduced by 50% of peak activation, for
macrophages after SCI is 47 weeks (Prüss et al., 2011). In
addition, macrophage activation persists at 45% of peak activa-
tion levels into chronic time points (42.5 months) (Prüss et al.,
2011). Collectively, this highlights SCI as a chronic wound condi-
tion in which macrophage activation is a strong contributing
factor (Fig. 1) (Shechter and Schwartz, 2013).
3.1. Phase 1: inﬂammation
The inﬂammatory phase of tissue repair is initiated by
damage and disruption of tissue homeostasis. In SCI this is
triggered by shearing and mechanical damage to cells and
spinal cord tissue. Immediately after injury, inﬂammatory
cells, including microglia and neutrophils, become activated
and home to the site of injury. After skin, muscle, and spinal
cord injuries, neutrophil accumulation begins within hours
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Donnelly and Popovich, 2008; Beck et al., 2010; Prüss et al.,
2011; Rigamonti et al., 2014). The primary functions of
inﬂammatory cells during this phase of repair are to remove
damaged tissues, facilitate removal of neutrophils, and
orchestrate the healing responses of ﬁbroblasts (or astrocytes
in the case of CNS injury), platelets, and endothelial cells
through the release of pro-inﬂammatory cytokines (Novak
and Koh, 2013a; Burda and Sofroniew, 2014). Unique features
of the SCI during this phase include disruptions of the blood–
spinal cord barrier (BSCB), activation and migration of NG2
positive, oligodendrocyte precursor cells (OPCs), and swelling
of endogenous astrocytes (Burda and Sofroniew, 2014). In
addition, myelin debris must be removed after SCI. The
unique components of CNS vs. skin or muscle injury during
this inﬂammatory phase has been reviewed previously
(Shechter and Schwartz, 2013; Burda and Sofroniew, 2014).
Macrophages in the inﬂammatory phase have cytokine
proﬁles similar to the M1 cells stimulated in vitro (Novak and
Koh, 2013b). Speciﬁcally, early after skeletal muscle and skin
injury, macrophages express high levels of TNF-α, IL-6, IL-12,
and IL-1β (Daley et al., 2010; Brancato and Albina, 2011).
Interestingly, macrophages in this phase also express high
levels of arginase and Ym1, two hallmark indicators of an
M2a macrophage activation (Table 1) (Mosser and Edwards,
2008; Daley et al., 2010). Collectively, this illustrates that
macrophages during the inﬂammatory phase of normal
wound repair adopt a mixture of M1 and M2a phenotypes
(Brancato and Albina, 2011) (Fig. 1 and Table 1).
Conceptually, these phenotypes make sense for this phase of
repair. Through the release of pro-inﬂammatory cytokines, M1
macrophages attract neutrophils and boost the inﬂammatory
response to facilitate removal of damaged tissues. M1 macro-
phages have enhanced phagocytic abilities that further facilitate
debris removal, bacterial removal and sterilization, and elimina-
tion of spent neutrophils. M2a cells, on the other hand, initiate
the proliferative phase of repair through release of anti-inﬂa-
mmatory cytokines, increase cell proliferation and migration via
release of arginase and Ym1, and promote the beginning of
tissue formation through secretion of growth factors (Sindrilaru
and Scharffetter-Kochanek, 2013; Novak and Koh, 2013a, 2013b).
A similar mixed M1 and M2a macrophage response occurs
early after SCI (Kigerl et al., 2009). Expression of the pro-
inﬂammatory markers IL-6, TNF-α, IL-1β, and IL-12 increases
acutely in response to SCI (Nocentini et al., 2008; Sato et al., 2012).
Macrophage arginase expression peaks within 1–3 dpi along with
other markers of M2a activation, IL-4, CD206, and Fizz-1 (Kigerl
et al., 2009; Kuo et al., 2011; Guerrero et al., 2012; Nakajima et al.,
2012; Thawer et al., 2013) (Fig. 1). In addition, neutrophil
accumulation begins within hours of SCI and, regardless of
species, peaks within the normal timeframe of the inﬂammatory
phase (1–3 days post-injury) (Kigerl et al., 2006; Beck et al., 2010;
Prüss et al., 2011). Collectively, these data highlight that the
macrophage and tissue responses are similar during the inﬂam-
matory phase between SCI and normally healing tissue.
3.2. Phase 2: proliferation
During normal healing, the proliferation phase consists of an
initial cell proliferation period around 2 dpi, a peak inproliferation around 5 dpi, and decreases proliferation around
10–12 dpi (Gurtner et al., 2008). Cells important for tissue
remodeling, e.g. endothelial cells and ﬁbroblast-lineage cells,
migrate and restore tissue integrity and barrier functions. During
this phase in most tissue types, angiogenesis, collagen deposi-
tion, tissue granulation, and ECM formation occurs. The unique
proliferative events after SCI include proliferation of glia and
neural progenitor cells and induction of scar-forming astrocytes
(Burda and Sofroniew, 2014). Analogous maturation initiated
during the later proliferation phase after SCI includes differen-
tiation of OPCs into oligodendrocytes, reduced axonal dieback
and stabilization, astrocytic scar formation, Wallerian degenera-
tion resolution, and BSCB repair. These events after SCI and
neurotrauma have been compared to the wound healing
responses after skin and muscle injury previously (Shechter
and Schwartz, 2013; Burda and Sofroniew, 2014). The implica-
tions from those papers, and other comprehensive analyses of
cellular events, indicate that the cellular responses occurring
during the proliferative phase are delayed or incomplete after
SCI (Donnelly and Popovich, 2008; Gensel et al., 2008; Mctigue
and Tripathi, 2008; Zhang and Gensel, 2014).
After skin and muscle wounds, macrophages in the prolif-
erative phase facilitate maturation of proliferating cells and
stabilization of damaged tissue (Novak and Koh, 2013a). Speciﬁ-
cally, macrophages facilitate initial cell proliferation during the
later inﬂammatory phase and maintain proliferation during the
proliferative phase then transition cells towardmaturation at the
end of the proliferative phase to start the remodeling phase
(Novak and Koh, 2013a). Macrophage depletion during the pro-
liferative phase in skin wounds disrupts vascular stability and
the transition from granulation tissue into newly formed, healing
scar tissue (Lucas et al., 2010). In circumstances of normal wound
healing, macrophages with decreased pro-inﬂammatory cyto-
kine proﬁles (decreased IL-12) and increased expression of anti-
inﬂammatory cytokines and growth factors (IL-10, TGF-β, Insulin-
like growth factor-1 (IGF-1)) drive the transition from inﬂamma-
tory to remodeling phases of repair (Lech and Anders, 2013).
M2 macrophages in the proliferative phase have different
phenotypic proﬁles than the M2 macrophages in the inﬂam-
matory phase (Daley et al., 2010). IL-10 is a key anti-
inﬂammatory cytokine produced by macrophages during the
proliferative stage of repair that facilitates tissue remodeling
(Thompson et al., 2013; Novak and Koh, 2013a). IL-10 release is a
hallmark of the M2b, or regulatory, macrophage phenotype
(Edwards et al., 2006; Mosser and Edwards, 2008). M2b macro-
phage activation, therefore, is essential in the middle to later
proliferative phase to trigger tissue remodeling (Edwards et al.,
2006; Mosser and Edwards, 2008; Lech and Anders, 2013). In
order to understand if the proliferative phase is properly
initiated after SCI we examined the gene expression of a
collection of markers associated with the M2b macrophage
phenotype. We detected a signiﬁcant decrease in genes asso-
ciated with the M2b phenotype from the initiation (3 dpi) to the
peak (7 dpi) of the proliferative phase (results summarized in
Fig. 1). Similarly, gene expression of IL-10 after SCI is decreased
by 6 dpi, a time of peak expression after normal wound healing
(Kuo et al., 2011; Novak and Koh, 2013a). Collectively, these data
highlight that the key macrophage phenotype regulating the
proliferative phase of repair, the M2b macrophage phenotype, is
improperly activated after SCI. It is likely, therefore, that SCI
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proliferative phase of repair (Shechter and Schwartz, 2013;
Novak and Koh, 2013a; Burda and Sofroniew, 2014).
Similarly, a number of typical proliferative events are initiated
within parallel time courses after skin/muscle injury and SCI,
however, these events are incomplete and do not result in
wound resolution. Proliferation of OPCs peaks within the ﬁrst
week of SCI and subsequent oligodendrocyte maturation occurs
2 weeks (Tripathi and Mctigue, 2007; Mctigue and Tripathi,
2008). Nonetheless, remyelination of denuded axons is incom-
plete and signal transduction remains impaired chronically (Imai
et al., 2008; Mctigue and Tripathi, 2008; Cao et al., 2010; James
et al., 2011; Powers et al., 2012). ECM and collagen formation after
SCI follows a similar time course to that of skin and muscle
wounds (Gurtner et al., 2008; Burda and Sofroniew, 2014; Gaudet
and Popovich, 2014), however, components of the ECM drive
protracted inﬂammation and impair wound closure (Gaudet and
Popovich, 2014). Similarly, the BSCB remains patent for over a
month to small molecules after SCI which further illustrating
that maturation events are not properly completed (Popovich
et al., 1996; Schnell et al., 1999; Zhang and Gensel, 2014).
Altering macrophage phenotypes has the potential to facil-
itate a more constructive proliferate phase. OPC differentiation
and maturation can be facilitated through activation of M2a and
M2c macrophages (Miron et al., 2013). After peripheral nerve
injury, macrophages are attracted to areas of Wallerian degen-
eration within 2–4 dpi (George and Grifﬁn, 1994). As a result,
myelin and axon clearance is complete within two weeks and
subsequently, the injured nerve heals (George and Grifﬁn, 1994).
In contrast, the SCI macrophage response is delayed in areas of
Wallerian degeneration and debris remains for months after SCI
(George and Grifﬁn, 1994). Debris can be removed in a timely
fashion by boosting the macrophage response to SCI suggesting
that manipulating macrophages may facilitate maturation
events typical of normal wound healing (Perrin et al., 2005;
Vallières et al., 2006). Following SCI, injured axons retract from
the injury site over time. The initial trauma causes an early
phase of axon retraction (1–2 dpi) but Silver and colleagues have
demonstrated that later of phases of retraction are caused by
activated macrophages (Horn et al., 2008; Busch et al., 2009, 2010,
2011; Evans et al., 2014). In vitro only M1, and not M2, macro-
phages physically engage dystrophic axons causing them to
release supportive tethers and pull back from areas of high
inhibitory growth substrates (Horn et al., 2008). Altering macro-
phage phenotypes by driving an alternative activation state
indicative of an M2b phenotype (high IL-10, IL-1b and low Arg-
1, CD206; see Fig. 9 in Stirling et al. (2014)) reduces axon dieback
(Stirling et al., 2014). Collectively, these ﬁnding suggest that
altering macrophages responses, speciﬁcally by boosting M2b
and M2c macrophage phenotypes, may orchestrate the prolif-
erative phase of wound healing to promote SCI repair (Fig. 1).
3.3. Phase 3: remodeling
The third and ﬁnal phase of normal wound healing, the
remodeling phase, begins 2–3 weeks after injury and can lasts
for months to years (Gurtner et al., 2008). During this phase, cells
that proliferated during the previous phase mature into new
tissue. Processes initiated during previous phases generally wind
down and eventually cease including inﬂammation, scarring,and angiogenesis. In muscle and skin wounds, collagen and ECM
and breakdown reaches a steady state leading to wound con-
tracture (Velnar et al., 2009). Growth factors (e.g. PDGF, TGF-β,
FGF), matrix metalloproteinases, and others regulate this phase
of the healing process and strengthen repaired tissue (Gurtner
et al., 2008; Velnar et al., 2009). Ultimately the remodeling phase
concludes with complete wound repair.
Although macrophages in the remodeling phase have an
identiﬁable M2c phenotype, as indicated by increased expres-
sion of CD206, CD163, and TGF-β and decreased expression of
the markers associated with an M2a or M2b phenotype: VEGF,
arginase-1 and IGF-1 (Daley et al., 2010; Mirza and Koh, 2011;
Novak and Koh, 2013a), their roles are not well understood.
Macrophages likely play a greater role by inhibiting, rather
than promoting, different aspects of the remodeling phase.
Indeed, macrophage depletion during this phase does not
affect scar formation and collagen production (Lucas et al.,
2010) but instead a maintained pro-inﬂammatory macrophage
presence is associated with a non-resolving, chronic wound
state in various tissues (Wang et al., 2007; Hu et al., 2011;
Sindrilaru et al., 2011; Rigamonti et al., 2014).
Little is known regarding the role macrophages play during
the remodeling phase after SCI. This is due in part because
remodeling events that occur endogenously after SCI do not lead
to successful healing and thus the remodeling phase is not
properly executed (Beattie et al., 1997). In addition, to the best of
our knowledge, phenotypic characterization of M2c macro-
phages has not been performed after SCI with the exception of
the preliminary short-term classiﬁcation done to generate Fig. 1.
Depletion studies similar to the ones examining the role of
macrophages during different phases of repair after skin injury
have also not been performed after SCI (Lucas et al., 2010).
Additional studies in these areas could provide insight into the
role of macrophages in later stages of SCI wound resolution.
Proper macrophage-mediated transitions through the phases
of repair are inﬂuenced by injury severity, age, health of the
individual, infections, and not of least importance, the biochem-
ical milieu and tissue speciﬁcs of the injury. Changes in the
mechanical, cellular, and biochemical makeup of the damaged
tissue can inﬂuence macrophage phenotype and therefore the
healing response. The relative contribution of speciﬁc factors
present at the SCI site on macrophage phenotypes is not well
understood. However, the initiation of secondary injury processes
likely inﬂuences macrophage activation and contributes to the
failure of macrophage-mediated wound healing. The effects of
secondary injury processes on macrophage activation after SCI
have been discussed previously (David and Kroner, 2011; Gensel
et al., 2011, 2012; Hawthorne and Popovich, 2011; Ren and Young,
2013). Only a few of these processes are discussed below.4. Secondary spinal cord injury processes
and macrophage activation
4.1. Reactive oxygen species
Reactive oxygen and nitrogen species (ROS and RNS respec-
tively) such as superoxide, hydroxyl radical, singlet oxygen,
hydrogen peroxide, and peroxynitrite form after SCI (Bains and
Hall, 2012). These free radicals participate in cell signaling under
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of ROS and RNS during pathophysiological conditions such as
SCI may overwhelm cellular antioxidant defense and ultimately
result in oxidative stress and secondary injury (Jia et al., 2012).
ROS and RNS may also contribute to secondary injury process
through maladaptive macrophage activation.
Major sources of ROS after SCI include mitochondria and
phagocytic cells. Mitochondria consume approximately 90% of
available oxygen during oxidative phosphorylation. Structural
and functional mitochondrial changes following SCI can there-
fore augment ROS formation (Wingrave et al., 2003). Phagocytic
neutrophils and macrophages also produce excessive ROS after
SCI. In phagocytes, superoxide after SCI is mainly produced by
the enzymatic activity of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase. Following SCI, phagocytic cells
increase oxygen consumption and generate superoxide through
activation of NADPH oxidase (Taoka et al., 1997). Other potential
biological sources of ROS/RNS associated with the pathogenesis
of SCI include cytosolic oxidases (e.g. xanthine oxidase), activa-
tion of the arachidonic acid cascade (e.g. Cyclooxygenase-2
(COX-2)), and activation of inducible nitric oxide synthase
(iNOS) (Hall and Springer, 2004; Conti et al., 2007; Jia et al., 2012).
The impact of this ROS and RNS rich environment on
macrophage phenotypes after SCI is largely unexplored. ROS
are involved in the activation process of M1 macrophages, in
part, through NF-κB (nuclear factor-kappa light-chain-
enhancer of activated-B cells) (Brüne et al., 2013), however,
speciﬁc ROS effects are difﬁcult to discern, mainly due to the
nonspeciﬁc effects of the antioxidants available (Gloire et al.,
2006). A variety of redox-sensitive proteins participate in the
signaling pathways that are triggered by inﬂammatory med-
iators (Forman and Torres, 2001). Thus, it is challenging to
elucidate how oxidative stress, resulting from SCI, regulates
the polarization of macrophages into different subtypes. It is
possible that ROS or ROS-induced products generated upon
SCI interfere with macrophage-mediated transitions between
the different phases of wound repair.
4.2. Lipid peroxidation
Lipid peroxidation occurs when free oxygen radicals react with
polyunsaturated fatty acids and cause oxidative degradation of
lipids (Bains and Hall, 2012). Highly reactive hydroxyl radicals
react with membrane polyunsaturated fatty acids, i.e. mem-
brane lipids, and superoxide anions reacts with nitric oxide, to
form peroxynitrite that then initiates lipid peroxidation. The
oxygen radicals oxidize the double bonds of unsaturated fatty
acids of phospholipids, resulting in the formation of toxic
phospholipid byproducts such as oxidized phosphatidylcho-
line (OxPC), 4-hydroxynonenal (4-HNE), and acrolein. Perox-
idation of lipids disrupts cellular membrane ﬂuidity and
permeability, interrupts metabolic process, and changes ion
transport systems (Nigam and Schewe, 2000).
The time course of byproduct formation is well character-
ized after SCI; levels of 4-HNE increase as soon as 3 h, peaks
at 24 h, and remain high for up to 2 weeks (Xiong et al., 2007).
Elevation of acrolein, which is the strongest electrophile
among all α,β-unsaturated aldehydes, has also been detected
following SCI (Luo et al., 2005; Hamann et al., 2008). These
overproduced aldehyde fragments in turn covalently bind toproteins and interrupt normal protein functions (Adibhatla
et al., 2003).
The effects of oxidized lipid and lipoproteins onmacrophage-
mediated SCI wound healing processes are unclear. In athero-
sclerosis, macrophage phenotypic polarization can be modiﬁed
by lipid mediators (Adamson and Leitinger, 2011). Oxidatively
modiﬁed lipid and lipoproteins act as “danger signals” and
activate macrophage toll-like receptors (TLRs). For instance,
binding of oxidized low-density lipoprotein (oxLDL) to CD36 in
combination with TLR heterodimers activates pro-inﬂammatory
processes (Seimon et al., 2010; Stewart et al., 2010). Lipids-
induced activation of TLRs in macrophages triggers NF-κB,
MAP kinase, and ROS-dependent signaling pathways, resulting
in the expression of pro-inﬂammatory genes and an M1-like
phenotype (Adamson and Leitinger, 2011). In addition, accumu-
lation of oxLDL attenuates the anti-inﬂammatory transcription
factor, kruppel-like factor 2 (KLF2) and shifts M2 macrophages
toward a pro-inﬂammatory phenotype (van Tits et al., 2011).
Phospholipids may also alter macrophages phenotypes indir-
ectly as OxPC on apoptotic cells enhances pro-inﬂammatory
monocyte adhesion and activation (Chang et al., 2004; Bratton
and Henson, 2005). Further studies are needed to clarify how
these secondary injury processes affect macrophage-mediated
transitions among different phases of wound healing.
4.3. Transcriptional control of macrophage activation
Macrophage phenotypes are regulated through transcriptional
events. For example, signaling through the transcription factors:
NF-κB, STAT1, and interferon regulatory factor 5 (IRF5) drive
pro-inﬂammatory, M1 macrophage activation (Lawrence and
Natoli, 2011). Speciﬁcally, a wide spectrum of pro-inﬂammatory
cytokines and chemokines such as TNFα, IL-1β, IL-6 and CCL2,
as well as ROS, are induced through these signaling cascades
(Mosser and Edwards, 2008; Van Assche et al., 2011) (31, 32). In
contrast, transcription factors regulating M2-type macrophage
activation include STAT6, IRF4, and peroxisome proliferator-
activated receptors (PPARs) (Lawrence and Natoli, 2011). We
highlight a few transcription factors that may inﬂuence macro-
phage activation after SCI below. For further discussion regard-
ing how transcription factors inﬂuence macrophage activation
states after SCI readers are referred to the following reviews:
(David and Kroner, 2011; Gensel et al., 2012; Mandrekar Colucci
et al., 2013; Ren and Young, 2013).
PPARs are a family of ligand-activated transcription factors
that play important roles in cellular processes including mito-
chondrial respiration, fatty acid metabolism, muscle lipid
metabolism, and cell differentiation (Mandrekar Colucci et al.,
2013). Three isoforms of this family have been described:
PPARα, PPARβ (or PPARδ) and PPARγ. Their expression has been
detected in microglia, astrocytes, neurons and oligodendro-
cytes in the CNS (Kliewer et al., 1994). Importantly, PPARβ and
PPARγ have been implicated as critical transcriptional “gate-
keepers” controlling the transcriptional components that inﬂu-
ence macrophage phenotype activation. Activation of PPARs
inhibits M1 gene expression in the presence of M1-type stimuli
and enhances M2 gene expression in cells exposed to M2-type
stimuli. Particularly, PPAR activation in macrophages causes
the induction of M2 markers including Arg1, CD206, Ym1 and
FIZZ1 and the effect is lost in PPAR deﬁcient mice (Bouhlel
b r a i n r e s e a r c h 1 6 1 9 ( 2 0 1 5 ) 1 – 1 18et al., 2007; Odegaard et al., 2007, 2008; Gallardo-Soler et al.,
2008; Kang et al., 2008). Animals with a functional deletion of
PPARγ in myeloid lineage cells also fail to generate wound-
healing responses (Odegaard et al., 2007). Thus there appears
to be a role for PPARγ in controlling alternative macrophage
activation and ultimately facilitating macrophage-mediated
wound repair.
In macrophages, PPARγ initiates a potent anti-inﬂammatory
response. PPARγ transactivates M2 genes (e.g. CD206) by binding to
the PPAR-responsive element (PPRE) sequence motif (Nicholson,
2004; Bouhlel et al., 2007). It also acts in a non-DNA-bound style,
which involves protein-protein interactions between PPARγ and
transcription factors participating in pro-inﬂammatory gene acti-
vation, such as AP-1, NF-AT, NF-κB, and STAT-1 (Ricote and Glass,
2007). By scavenging these transcription factors, PPARγ can block
the production of pro-inﬂammatory genes. PPARγ is also able to
bind to transcriptional coactivators, such as steroid receptor co-
activator 1 or p300/CBP, inhibiting AP-1 activation and reducing
NF-κB-dependent gene expression (Pascual et al., 2005; Brüne
et al., 2013). In addition, PPARγ can interfere with protein kinase
C-α (PKCα) cellular membrane translocation and thus block its
activation. Inhibition of PKCα activity attenuates ROS production.
The anti-inﬂammatory effect of PPAR activation has been
reported to be beneﬁcial in several CNS injury and disease
models, including traumatic brain injury (TBI), SCI, multiple
sclerosis (MS), stroke, and amyotrophic lateral sclerosis (ALS)
(Kiaei et al., 2005; Schütz et al., 2005; Drew et al., 2006; Yi et al.,
2008; Villapol et al., 2012). For example, activation of PPARγ
attenuates neuroinﬂammation and increases M2 macrophages
in the model of Alzheimer's disease (AD), suggesting that adm-
inistration of PPAR agonists may create an inﬂammatory milieu
in the CNS favoring regeneration and recovery (Mandrekar
Colucci et al., 2012). Activation of PPARβ in macrophages
enhances the clearance of apoptotic cells through increased
expression of macrophage opsonins (Mukundan et al., 2009). In
models of MS and AD, activation of PPAR in microglia is neur-
oprotective by promoting phagocytosis of pathological protein
aggregates (Mandrekar Colucci et al., 2012; Yamanaka et al.,
2012). In addition, PPARγ activation increases the phagocytotic
capability of microglia through upregulation of the scavenger
receptor CD36 (Yamanaka et al., 2012). Because of the high
production of myelin and cell debris following SCI, M2 activation
induced by PPARs may be beneﬁcial in promoting debris rem-
oval and thus facilitating macrophage-mediated transition from
inﬂammatory to proliferative phases of repair.5. Summary
It is unlikely that activation of a single macrophage phenotype
can facilitate proper wound healing following SCI. Successful
orchestration of macrophage-mediated tissue repair requires
ﬁne tuning different macrophage phenotypes to harmoniously
facilitate transitions among different wound healing phases.
Activating macrophage in concert may be achieved through
transcriptional manipulations but secondary injury process,
including the formation of reactive oxygen species and lipid
peroxidation, promise dissonance. Determining which pheno-
types we should be enhance and which we should abate to
facilitate proper healing requires further investigation and willlikely depend upon the injury-speciﬁc tissue microenviron-
ment and the desired phase of repair.Acknowledgments
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